The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 6.56 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.26 — no flag raisedOK
- Earnings quality 84/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Cytek Biosciences, Inc. reports it. History and quarterly detail are in the app.
- Product$144.2M
- Service$57.3M
Leadership changes
From Cytek Biosciences, Inc.'s own filings, the day they're filed.
- Philippe Busque · President · departureeff. 2026-06-05
- Paul Christopher Williams · Chief Operating Officer · departureeff. 2024-09-27
- Patrik Jeanmonod · Chief Financial Officer · departureeff. 2024-03-17
Latest filings
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-25
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cytek Biosciences, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Cytek Biosciences, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.